Compare AMST & BRTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMST | BRTX |
|---|---|---|
| Founded | 2017 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Prepackaged Software | Managed Health Care |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4M | 6.3M |
| IPO Year | 2020 | 2015 |
| Metric | AMST | BRTX |
|---|---|---|
| Price | $1.16 | $0.41 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 266.3K | ★ 25.4M |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 40.46 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $110,459.00 | $81,000.00 |
| Revenue This Year | N/A | $298.39 |
| Revenue Next Year | N/A | $64.62 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.77 | $0.16 |
| 52 Week High | $4.78 | $1.89 |
| Indicator | AMST | BRTX |
|---|---|---|
| Relative Strength Index (RSI) | 41.86 | 58.72 |
| Support Level | $0.88 | $0.20 |
| Resistance Level | $2.12 | $1.20 |
| Average True Range (ATR) | 0.10 | 0.05 |
| MACD | -0.03 | -0.00 |
| Stochastic Oscillator | 0.03 | 78.45 |
Amesite Inc is an artificial intelligence-driven platform and course designer that rapidly provides customized, high-performance and scalable online products for schools and businesses. The company helps educational institutions and businesses improve learning as their technology partner, delivering a disruptive technology driven by AI and offers a constellation of services that help partners implement new programs, and improve existing ones. Its customers are Enterprises, universities, and K-12 schools.
BioRestorative Therapies Inc is a biotechnology company based in the United States. It focuses on the development of regenerative medicine products and therapies using cell and tissue protocols, involving adult (non-embryonic) stem cells. The company's two core development programs include the Disc/Spine Program, which involves cell therapy candidate, BRTX-100, a product formulated from autologous cultured mesenchymal stem cells collected from the patient's bone marrow; and the Metabolic Program, which includes the development of cell-based therapy to target obesity and metabolic disorders using brown adipose-derived stem cells, to generate brown adipose tissue.